Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors

Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X:          .

“92 Circulating-immuno-oncology-related proteins in patients with metastatic PDAC (Pancreatic Ductal Adenocarcinoma) from the CheckPAC trial who responded to radiotherapy +nivolumab ± ipilimumab.

High FASLG (FAS ligand) and Gal-1 lead to higher PFS (progression-free survival)

Circulating immune-related proteins might predict the efficacy of ICIs (Immune Checkpoint Inhibitors).”

Proceed to the article.
Source: Angelo Pirozzi/X